LongBio Pharma's (HKG:1779) seasonal allergic rhinitis treatment LP-003 met the main goal of a phase 3 study, the firm said in a Hong Kong bourse filing Friday.
According to LongBio, the late-stage study in China met its pre-specified primary endpoints with "highly statistically and clinically significant" results.
The firm enrolled 546 patients in the study, including those who did not achieve satisfactory results with standard treatment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments